Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel cellular therapies for hepatobiliary malignancies.
Xue JN, Wang YY, Wang YC, Zhang N, Zhang LH, Lu ZH, Zhao LJ, Zhao HT. Xue JN, et al. Among authors: zhang n, zhang lh. Hepatobiliary Pancreat Dis Int. 2022 Oct;21(5):450-454. doi: 10.1016/j.hbpd.2022.08.014. Epub 2022 Sep 6. Hepatobiliary Pancreat Dis Int. 2022. PMID: 36100543 Review.
Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY, Yang X, Wang YC, Long JY, Sun HS, Li YR, Xun ZY, Zhang N, Xue JN, Ning C, Zhang JW, Zhu CP, Zhang LH, Yang XB, Zhao HT. Wang YY, et al. Among authors: zhang n, zhang lh, zhang jw. World J Gastroenterol. 2023 Mar 14;29(10):1614-1626. doi: 10.3748/wjg.v29.i10.1614. World J Gastroenterol. 2023. PMID: 36970591 Free PMC article.
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Zhu C, Li H, Yang X, Wang S, Wang Y, Zhang N, Wang Y, Xue J, Zhang L, Ning C, Yang X, Xun Z, Chao J, Long J, Sang X, Zhu Z, Zhao H. Zhu C, et al. Cancer Immunol Immunother. 2023 Sep;72(9):2949-2960. doi: 10.1007/s00262-023-03466-8. Epub 2023 May 29. Cancer Immunol Immunother. 2023. PMID: 37247023 Free PMC article.
Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.
Chao J, Wang S, Wang H, Zhang N, Wang Y, Yang X, Zhu C, Ning C, Zhang X, Xue J, Zhang L, Piao M, Wang M, Yang X, Lu L, Zhao H. Chao J, et al. Cancer Immunol Immunother. 2023 Nov;72(11):3717-3726. doi: 10.1007/s00262-023-03523-2. Epub 2023 Oct 3. Cancer Immunol Immunother. 2023. PMID: 37787790 Free PMC article.
1,315 results